| CAS NO: | 1638178-87-6 |
| Cas No. | 1638178-87-6 |
| Canonical SMILES | O=C1N(CC2=CC=C(F)C=C2F)C3=NCCN3C4=C1CN(CC5=CC=CC=C5)CC4 |
| 分子式 | C23H22F2N4O |
| 分子量 | 408.44 |
| 溶解度 | DMSO: 100 mg/mL (244.83 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | ONC206 is an analogue of TRAIL inducer ONC201[1]. ONC206 is a selective antagonist of the D2-like dopamine receptors (DRD2/3/4) at nanomolar concentrations. ONC206 has broad-spectrum anti-tumor activity[2]. ONC206 selectively antagonizes the D2-like (DRD2/3/4), but not the D1-like (DRD 1/5), subfamily of dopamine receptors[2].ONC206 significantly inhibits tumor cell migration and invasion in vitro[1].ONC206 (0.05 μM; Over 48 hours) inhibits migration of ONC201- and TRAIL-resistant HCT116 Bax-/- cells without inducing cell death or inhibiting cell proliferation[1].ONC206 engages the ISR and TRAIL pathway leading to tumor growth arrest and cell death[1].ONC206 does not induce cell cycle arrest in a colorectal cell line with acquired ONC201-resistance[1]. Cell Proliferation Assay[1] Cell Line: HCT116 cells ONC206 (100 mg/kg;p.o.; every 10 days) causes significant tumor growth inhibition[2]. [1]. Wagner J, et al. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16(19):1790-1799. [2]. Varun Vijay Prabhu, et al. Potent anti-cancer activity of the imipridone ONC206: A selective dopamine D2-like receptor antagonist. AACR Annual Meeting 2017, April 1-5, 2017; Washington, DC. |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |